ABSTRACT Diabetic foot ulcer treatment currently focuses on targeting bacterial biofilms, while dismissing fungi. To investigate this, we used an in vitro biofilm model containing bacteria and fungi, reflective of the wound environment, to test the impact of antimicrobials. Here we showed that while monotreatment approaches influenced biofilm composition, this had no discernible effect on overall quantity. Only by combining bacterium-and fungus-specific antibiotics were we able to decrease the biofilm bioburden, irrespective of composition.
D
iabetic foot ulcers (DFU) are an increasing health care burden and cause excessive amounts of patient morbidity and mortality. It is known that infection both impairs healing and is linked to the recurrence of ulcers (1) . It has been shown that chronic wounds often harbor pathogenic biofilms of a polymicrobial nature and are commonly recalcitrant to treatment (2) (3) (4) (5) . Guidelines suggest the initial use of oral antibiotics for empirical therapy with activity against Grampositive organisms, especially penicillins such as flucloxacillin (6, 7) . Further coverage is provided by other antibiotics, such as the fluoroquinolone ciprofloxacin (7) . Despite these chemotherapeutic approaches, resolution of infection is often hindered because of the failure to account for coinfecting pathogenic fungi (8) . Indeed, fungal infection in DFUs is underrecognized, although recently some studies have begun to shed light on the significant involvement of the wound mycobiome (9) . While antifungal treatments have been shown to improve DFU outcome, they are only used routinely to treat superficial fungal infections in diabetics, such as onychomycosis (10, 11) . Therefore, it is not a great leap to suspect fungal components as a key contributor to pathogenic DFU biofilms.
Characterized laboratory strains were used to create biofilms in standard 96-well plates, including the bacteria Pseudomonas aeruginosa PA14 and Staphylococcus aureus ATCC 13420 and the yeast Candida albicans SC5314 (12) . Biofilm antimicrobial susceptibility testing was carried out as described previously by our group to determine the sessile MICs (13) . Briefly, monospecies and coculture biofilms were grown in Mueller-Hinton broth (bacterial cultures) or RPMI broth (fungal cultures) before being treated with the flucloxacillin, ciprofloxacin, or fluconazole (Sigma, Dorset, United Kingdom), which are common clinically at a range of concentrations (0.125 to 128 mg/liter) (6, 7, 11) . Viability posttreatment was assessed using alamarBlue metabolic dye. Here it was shown that an increase in species diversity leads to elevated viability following treatment ( Fig. 1 ; P Ͻ 0.01), as evidenced by S. aureus coculture and triadic biofilms after ciprofloxacin therapy. A similar, but less dramatic, effect was observed with flucloxacillin, although for fluconazole, no discernible effect was observed (see Fig. S1 in the supplemental material). This indicates that the increased complexity of a biofilm community and physical structure provided by C. albicans lead to enhanced resistance, as has been shown elsewhere (14, 15) .
Our group has recently created and described an in vitro interkingdom biofilm model that reflects a chronic wound environment, a model formed within a threedimensional cellulose matrix (12) . We therefore aimed to use this model to characterize in vitro responses to antibiotic pressure in a triadic interkingdom biofilm model that is reflective of the chronic wound environment. Triadic biofilms in the cellulose model were created by standardizing all three microorganisms to 1 ϫ 10 6 CFU/ml in phosphate-buffered saline (PBS) and incubating them with 1.25-cm 2 sections of cellulose matrix for 2 h at 37°C with agitation. The matrix was then placed on top of a 50% serum hydrogel surface and incubated at 37°C for 24 h (12) . Following biofilm development, these were treated with 128 mg/ml flucloxacillin, ciprofloxacin, and fluconazole, either alone or in combination, for a further 24 h at 37°C alongside untreated controls. All testing was carried out in triplicate on three separate occasions. To differentiate between live and dead cells, a quantitative PCR (qPCR)-based assay (16) (17) (18) (19) was used to assess the viable composition of the biofilms with species-specific primers (12, 19) . This assay utilizes propidium monoazide, a DNA intercalating dye, which binds to DNA in cells with a compromised membrane preventing this DNA from being amplified in downstream PCR. Therefore, only DNA from viable cells with intact membranes is detected. MasterPure yeast DNA extraction kits were used as per the manufacturer's instruction (Epicentre, Cambio, Cambridge, United Kingdom) to process all samples. For qPCR, a Fast SYBR green master mix (Life Technologies, Paisley, United Kingdom) was used with the primer sequences and thermal profile previously defined (12) . Each sample was analyzed in duplicate using a Step One real-time PCR system and software (Life Technologies, Paisley, United Kingdom). Samples were quantified to calculate the colony-forming equivalents (CFE) based upon a standard curve per reaction performed. Results were also confirmed by CFU counts using the Miles and Misra technique (20) .
The cellulose matrix model has already been shown to create more resilient biofilms (12) , and when treated with elevated levels of antibiotics (128 mg/liter), there was little impact on the viable cells within the matrix, although compositionally the biofilms were affected (Fig. 2A) . This implies that elimination of one microbial component of the biofilm through targeted therapy creates a niche for the other species to thrive. For example, fluconazole treatment significantly decreased C. albicans by approximately 1 ϫ log 10 (P Ͻ 0.05). In contrast, a combined treatment with flucloxacillin-ciprofloxacin resulted in a 3-fold increase in C. albicans (Fig. 2B) . In addition to consideration of the biofilm composition, the biovolume is equally important, given that a C. albicans cell is approximately 10 times the size of an S. aureus cell. Consequently, even in biofilms where C. albicans is in low abundance, the yeast and hyphal cells still provide physical structure and support to biofilm through its spatial dominance. The only treatment observed to cause a substantial decrease in all three microbial components and an overall reduction in viable cell composition was the combination of all three antimicrobials (Fig. 3) . Hierarchical clustering analysis also shows that the C. albicans population is very closely linked to the total CFE present, suggesting it is a key driving force within the biofilm community (Fig. 3) .
The data from this investigation suggest that antifungal drugs should be included in empirical therapy options alongside antibiotics. It has been recently shown that the hyphal structure and extracellular matrix of C. albicans mycofilms support bacterial growth, leading to more resilient biofilms in terms of antibiotics and antifungals (14, 15) . These key findings indicate that disrupting and/or impeding this supportive mycofilm structure could lead to a physical collapse of the polymicrobial community. Fungi are increasingly recognized as a key contributor to biofilms in DFUs, and we have shown here that C. albicans appears to be an important element behind the recalcitrant nature of these biofilms. Therefore, it is imperative to consider a treatment covering Treated biofilms were compared to untreated controls using a two-tailed unpaired t test (*, P Ͻ 0.05). Pa/PA, P. aeruginosa; Sa/SA, S. aureus; Ca/CA, C. albicans.
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Antimicrobial Agents and Chemotherapy these major pathogens, rather than considering them as having a supporting role. Inclusion of antifungals in routine treatment strategies could allow for easier disruption of the biofilm, decreasing microbial load in DFUs and ultimately improving patient outcomes.
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